ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1916

Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus

Carmen Lasa Teja1, Carolina Aguirre-Portilla2, Virginia Portilla González3, Carmen Bejerano-Herreria2, Alfonso Corrales-Martínez4 and Ricardo Blanco5, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, 4Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 5Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Meeting: ACR Convergence 2025

Keywords: Access to care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1914–1935) Health Services Research Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) are at a higher risk of persistent HPV infection and developing premalignant cervical lesions and cervical cancer. High-risk oncogenic HPV genotypes, particularly types 16 and 18, are the primary causal agents in most cases. Cervical cancer screening using HPV testing and cytology enables early detection of precursive lesions, preventing their progression to invasive cancer. The study aimed to evaluate adherence to the cervical cancer screening program in women with Systemic Lupus Erythematosus of reproductive age. Additionally, it sought to identify the most prevalent high-risk HPV genotypes within this population.

Methods: A retrospective observational study was carried out in a cohort of 128 women with SLE aged 20-50 years, followed in the outpatient rheumatology clinic of a tertiary care hospital in northern Spain.

Results: A total of 128 women were included, with a mean age of 39.11 ± 7.91 years and a mean disease duration of 11.16 ± 7.53 years (Table 1). Among them, 19.53% had never undergone cytology or HPV testing. Among the 80.46% who participated in screening, only 34.37% adhered to the recommended intervals (every three years or less), while the remainder were screened sporadically or outside the established periodicity. A total of 22.65% underwent screening at least once, and 23.43% were screened two or more times without following the recommended intervals. Regarding HPV infections, 18.75% tested positive, predominantly for high-risk genotypes (17.18%), with 8.59% showing coinfection with low-risk genotypes. Genotype 16 was the most frequently identified among high-risk infections (Figure 1). Cervical lesions related to HPV were detected in 14.06% of the women, with 9.37% presenting high-grade lesions (HSIL) and 4.68% presenting low-grade lesions (LSIL). Cervical cancer was diagnosed in 7.03% of the cases, with two patients presenting associated intraepithelial neoplasia of the vagina and vulva. Regarding smoking habits, 21.09% of the women were active smokers, 26.56% were former smokers, and 52.34% had never smoked. No statistically significant association was found between tobacco use and cervical cancer in this cohort (p = 0.0735).

Conclusion: The findings reveal a high prevalence of high-risk HPV infections in women with SLE, associated with a considerable risk of progression to premalignant lesions and cervical cancer. However, low adherence to the screening program was observed, highlighting the need for strategies to promote greater participation in such programs.

Supporting image 1Table 1. Epidemiological characteristics and results of women with SLE (n=128)

Supporting image 2Figure 1. Identified high-risk (HR) HPV genotypes. N&#3f 22 patients


Disclosures: C. Lasa Teja: None; C. Aguirre-Portilla: None; V. Portilla González: None; C. Bejerano-Herreria: None; A. Corrales-Martínez: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Lasa Teja C, Aguirre-Portilla C, Portilla González V, Bejerano-Herreria C, Corrales-Martínez A, Blanco R. Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/adherence-to-cervical-cancer-screening-programs-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-cervical-cancer-screening-programs-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology